This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

RBC Capital Reaffirms Their Buy Rating on Biogen (BIIB)

Tipranks - Tipranks - Thu May 28, 6:52AM CDT

In a report released today, Brian Abrahams from RBC Capital maintained a Buy rating on Biogen, with a price target of $227.00.

Memorial Day Sale – Claim 70% Off TipRanks

Abrahams covers the Healthcare sector, focusing on stocks such as Gilead Sciences, Regeneron, and Biogen. According to TipRanks, Abrahams has an average return of 10.9% and a 51.30% success rate on recommended stocks.

In addition to RBC Capital, Biogen also received a Buy from William Blair’s Myles Minter in a report issued on May 22. However, on May 18, Wedbush maintained a Hold rating on Biogen (NASDAQ: BIIB).

See the top stocks recommended by analysts >>

Based on Biogen’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $2.48 billion and a net profit of $319.5 million. In comparison, last year the company earned a revenue of $2.43 billion and had a net profit of $240.5 million

Read More on BIIB:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).